| Literature DB >> 35453283 |
Xiaojie Qin1, Mingzhe Yang1, Hua Cai2, Yangtai Liu1, Leon Gorris3, Muhammad Zohaib Aslam1, Kai Jia1, Tianmei Sun1, Xiang Wang1, Qingli Dong1.
Abstract
Antibiotic resistance in Salmonella is a global public health problem. Salmonella enterica serovar 1,4,[5],12:i:- (S. 1,4,[5],12:i:-), a monophasic variant of Salmonella Typhmurium, is one of the leading Salmonella serovars in several countries. This study aimed to assess the prevalence of antibiotic resistance to this serovar in China through a systematic review and meta-analysis. Nineteen eligible studies during 2011-2021 were included. A total of 4514 isolates from humans, animals, foods, and the environment were reported, which mainly concerned isolates found in Guangdong, Guangxi, Jiangsu, and Shanghai. A random-effects model was used to estimate the pooled resistance rate of S. 1,4,[5],12:i:-. Rates were found to be very high (values ≥ 75%) for tetracycline, ampicillin, sulfisoxazole, and streptomycin; high (50-75%) for nalidixic acid, amoxicillin-clavulanic acid, and chloramphenicol; and moderate (25-50%) for trimethoprim-sulfamethoxazole, kanamycin, trimethoprim, and gentamicin. The rates of resistance to ciprofloxacin, cefotaxime, ceftriaxone, cefepime, ceftazidime, and colistin were low (values ≤ 25%), but of great concern in terms of their current clinical importance. Furthermore, a high multidrug resistance rate (86%, 95% CI: 78-92%) was present in S. 1,4,[5],12:i:-, with the ASSuT pattern largely dominating. Subgroup analysis results showed that the high heterogeneity of resistance rates was not entirely dependent on isolated sources. Taken together, the severity of antibiotic resistance in S. 1,4,[5],12:i:- urgently requires the rational use of antibiotics in future infection control and antibiotic stewardship programs.Entities:
Keywords: Salmonella enterica serovar 1,4,[5],12:i:-; antibiotic resistance; meta-analysis; multidrug resistance
Year: 2022 PMID: 35453283 PMCID: PMC9031511 DOI: 10.3390/antibiotics11040532
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1PRISMA flowchart diagram for the selection process of eligible studies.
Figure 2Data on isolates of S. 1,4,[5],12:i:- extracted from eligible studies concerning (A) sources, (B) geographical locations in China, and (C) detection rates of antibiotic resistance genes.
Meta-analysis results concerning antibiotic resistance in S. 1,4,[5],12:i:- isolates in China.
| Antibiotics | Total Number of Isolates | Resistance Rate | Heterogeneity | |||
|---|---|---|---|---|---|---|
| Mean of Pooled Resistance Rate % | 95% CI (%) 1 |
| ||||
| Ampicillin | 4536 | 91 | 83–94 | 63 | <0.1 | |
| Amoxicillin–clavulanic acid | 579 | 70 | 26–94 | 96 | <0.1 | |
| Cefotaxime | 4151 | 19 | 12–29 | 89 | <0.1 | |
| Ceftazidime | 4128 | 10 | 7–15 | 74 | <0.1 | |
| Cefepime | 498 | 12 | 9–15 | 0 | 0.98 | |
| Ceftriaxone | 33 | 21 | 10–38 | 1 | 0.36 | |
| Aminoglycosides | Gentamicin | 4520 | 44 | 29–59 | 91 | <0.1 |
| Streptomycin | 1701 | 76 | 66–83 | 79 | <0.1 | |
| Kanamycin | 363 | 45 | 40–50 | 20 | 0.28 | |
| Sulfonamides | Trimethoprim–sulfamethoxazole | 3179 | 48 | 33–63 | 86 | <0.1 |
| Sulfisoxazole | 1347 | 86 | 76–93 | 83 | <0.1 | |
| Trimethoprim | 1340 | 45 | 39–52 | 83 | <0.1 | |
| Phenicols | Chloramphenicol | 4443 | 54 | 47–60 | 88 | <0.1 |
| Polymyxins | Colistin | 255 | 2 | 1–5 | — | — |
| Quinolones | Ciprofloxacin | 4532 | 22 | 15–32 | 90 | <0.1 |
| Nalidixic acid | 498 | 73 | 69–76 | 0 | 0.35 | |
| Tetracyclines | Tetracycline | 4447 | 93 | 90–95 | 46 | <0.1 |
1 CI: Confidence interval. 2 I2: Index for the degree of heterogeneity. 3 Cochran’s Q-test p value.
Meta-analysis results concerning MDR rates in S. 1,4,[5],12:i:- isolates in China.
| Multiple | Total Number of Isolates | MDR Rate | Heterogeneity | ||
|---|---|---|---|---|---|
| Mean of Pooled MDR Rate % | 95% CI (%) 1 |
| |||
| ≥3 | 2251 | 86 | 78–92 | 87 | <0.1 |
| ASSuT | 681 | 70 | 66–73 | 40 | 0.19 |
| ACSSuT | 319 | 29 | 18–43 | 74 | <0.1 |
| ACSuGSTTm | 616 | 27 | 24–31 | — | — |
1 CI: Confidence interval. 2 I2: Index for the degree of heterogeneity. 3 Cochran’s Q-test p value.
Figure 3Resistance rate of S. 1,4,[5],12:i:- to antibiotics by sampling sources. Antibiotics in the left picture: AMP, ampicillin; AMC, amoxicillin–clavulanic acid; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; CRO, ceftriaxone; GEN, gentamicin; STR, streptomycin; KAN, kanamycin. Antibiotics in the right picture: SXT, trimethoprim–sulfamethoxazole; SUL, sulfisoxazole; TMP, trimethoprim; CHL, chloramphenicol; CL, colistin; CIP, ciprofloxacin; NAL, nalidixic acid; TET, tetracycline. Lines indicate 95% confidence intervals.
Figure 4The pooled prevalence rates of MDR S. 1,4,[5],12:i:- in 13 Chinese provincial regions based on the eligible studies.